ICL Therapeutics has set its sights on a Series A funding round and an Initial Public Offering (IPO) following its most recent investment round.
The Motherwell-based biotech business claims to be on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections, including SARS-CoV-2.
ILC’s lead hybrid interferon drug, Alfacyte, is currently in development as an anti-viral medicine for the treatment of up-per respiratory tract viral infections, including the cause of Covid-19.